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Abstract
Gabapentin and pregabalin are drugs that act through reduction of the central sensitization. They are useful
in conditions such as partial seizures and neuropathic pain. However, in the last decade these drugs appear to
have been effective against a variety of other symptoms, such as pruritus, hot flushes in post-menopausal
women and intractable hiccups. The drugs are probably also effective for many other symptoms related to
central sensitization but the paucity of data does not allow for support of these claims. Both gabapentin and
pregabalin have a good safety record.
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Introduction
Gabapentin (GBP) and pregabalin (PGB) are two
drugs which have been recently developed to treat
partial seizures [1]. Both drugs also appear to have
been effective against neuropathic pain [2]. Al-
though the drugs resemble gamma-aminobutyric
acid (GABA), they do not have affinity to both GABAA
and GABAB receptors or interact with GABA trans-
porters. (For a review see Taylor 2007) [3].
The drugs show a high affinity to the a-2-d units
of voltage-gated calcium channels [3]. Binding to
the a-2-d units reduces the release of glutamate
from the hyper-excited neurones [4]. GBP and PGB
also decrease the release of substance P in the spi-
nal cord and, in this way, reduce the sensitization
of the spinal cord [5]. Reduction of central sensiti-
zation has been evidenced in healthy volunteers [6].
Apart from this effect, GBP and PGB increase the
concentrations of extracellular GABA. This happens
either by the stimulation of GABA release[7] or chang-
es in GABA metabolism by interaction with glutaminic
acid decarboxylase and GABA-transaminase [8].
Neither mechanism, the influence on voltage-
gated calcium channels or the increase of extracel-
lular concentrations of GABA, is specific to seizures
or pain and hence GBP and PGB may also have oth-
er pharmacological effects. The most important is
that both drugs have proven safety records at the
pharmacologically effective doses.
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The scope of the article
GBP and PGB are licensed for the treatment not
only of partial seizures but also postherpetic neu-
ralgia and PGB in Europe for the treatment of anxi-
ety disorders [3]. However, since the drugs were
introduced they have become very popular for the
treatment of many conditions unrelated to partial
seizures and neuropathic pain. In this article we
examine the evidence for these claims. Symptoms
encountered in psychiatry are excluded from this
review, as they deserve separate examination.
The hiccup
The hiccup-evoking centre is localized in the
medullary reticular formation lateral to the nucleus
ambiguus. These centres receive impulses from the
sensory vagal neurones and communicate with the
vagal motor neurones to, among others, the larynx
and diaphragm. This was investigated most thor-
oughly in cats [9, 10]. Hiccups are not specific to
any disease and more than 100 conditions are known
to be associated with this recalcitrant symptom [11].
Any increase of impulses from the periphery (irrita-
tion, inflammation) or decrease in the threshold of
the firing of the central neurones not counteracted
by the central inhibitory mechanisms, may result in
hiccups. It seems that hiccups may result from sen-
sitization of central neurones which may be attenu-
ated by GBP and PGB. Many remedies have been
invented through the centuries. Most of these rem-
edies increased the central inhibition of hiccups.
However, many of these remedies were only effec-
tive for acute hiccups. They are usually ineffective in
chronic and persistent hiccups, where there is a per-
manent irritation of the afferent nerve endings.
These impulses can be diminished by the increase
of the gastric and oesophageal pH with omepra-
zole [12]. Yet another approach, especially when
the cause of the hiccup is “central” and the firing
threshold is too low, is the use of anti-convulsive
treatments. In this area, baclofen was found to be
effective in small double-blind controlled trials [13,
14]. However, the use of baclofen in palliative care
is sometimes difficult because of adverse effects
such as somnolence. More recently GBP [15–21] and,
to a lesser extent, PGB [22] were described as being
effective in several series of patients with persistent
hiccups. This effect, although used widely, has not
been confirmed in formal controlled trials. The drugs
have a rapid onset of action, few adverse effects and
above all fewer interactions with other drugs [18].
GBP can thus be used alone or in combination with
other drugs such as omeprazole[21]. After discontin-
uation of treatment the hiccups may reoccur [17].
Tinnitus
Tinnitus is the annoying perception of sounds in
the absence of acoustic stimulation. Tinnitus com-
monly accompanies hearing loss and is more com-
mon in the elderly [23].Occasionally, an underlying
structural lesion (e.g. acoustic neuroma) or an oto-
logical disease (e.g. Meniere’s disease) is identified
as the cause of the tinnitus. More often, tinnitus
and hearing loss occur together without associated
conditions or structural lesions: as we consider it,
idiopathic subjective tinnitus. It is not known wheth-
er terminal disease and weakness are associated
with the increased frequency of tinnitus but occa-
sionally this symptom is encountered in the termi-
nally ill and is particularly difficult to treat. The patho-
genesis of tinnitus is unknown so when the treat-
ment is offered it is not usually based on the mech-
anism of tinnitus. Various mechanisms have been
proposed, including loss of central inhibition in
which many peripheral impulses, not necessarily
acoustic, are experienced as an annoying sound. It
is unclear whether this hypothesis originated be-
fore or after the first reports on the efficacy of anti-
convulsant drugs in tinnitus. Zapp was the first to
report the serendipitous effect of GBP on tinnitus in
one single patient [24]. In the study performed at
Washington University, GBP was claimed to decrease
the Tinnitus Handicap Inventory in a group of 19
patients treated for a week with GBP 900 mg a day
(http://www.auditio.com/tinnitus/aaa2000). Howev-
er, this study was never reported in a peer reviewed
journal. An uncontrolled study by Bauer et al sug-
gested that GBP given up to 2400 mg a day may be
effective in the treatment of tinnitus, especially when
it was associated with a history of acoustic trauma
[25]. In a double-blind controlled study of GBP (900–
3600 mg) in 59 patients treated through the GBP
arm, no effect of GBP was observed [26]. Similarly,
a prospective double-blind, placebo-controlled tri-
al with GBP by Bakhshaee et al included 30 pa-
tients [27]. The dose of GBP was gradually increased
to 900 mg a day. In this study there was no signif-
icant difference between the effect of the placebo
and GBP. In another study on 52 patients with
tinnitus randomized to the GBP arm, no effect of
GBP 1800 mg a day was observed [28].
It can thus be concluded that despite several
case reports suggesting a positive effect of GBP on
tinnitus, this effect can not be replicated and con-
firmed in controlled studies. There are no reports or
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even suggestions that PGB would be effective in
this context.
Hot flushes and sweating
Hot flushes and sweating are the most annoy-
ing symptoms of advancing menopause but are also
experienced by patients with breast and prostate
cancer [29, 30]. Sweating as a separate symptom
occurs in many forms of cancer, especially when
liver metastases are present and when the patient
is treated with opioids for pain [31, 32]. As treat-
ment with hormones has the potential to improve a
patient’s prognosis it is difficult to advise on dis-
continuing them. There is a lot of interest in finding
an “add-on” to hormonal treatment that would be
able to control these annoying symptoms. One of
the treatments that has recently emerged is one
with clonidine, GBP and SSRIs [33]. In a case series,
Guttuso reported that GBP appeared to be effective
in treating hot flushes in post-menopausal women
[34]. He later performed a placebo-controlled study
confirming these observations [35].In this study
performed on 59 post-menopausal women suffer-
ing severe hot flushes, GBP reduced the flush com-
posite score from 54% to 31% (p = 0.01). The dos-
es needed to achieve these results were up to 2700
mg of GBP daily. In a much larger study comprising
420 women with a history of breast cancer and hot
flushes during a course of treatment with tamoxifen,
Pandya et al found a 31% decrease in hot flushes
with a low dose of GBP (300 mg per day) and a 46%
reduction when the dose was increased to 900 mg
per day. In this study the placebo produced a reduc-
tion by 18%. The p was significant only for 900 mg
GBP per day [29]. In a small controlled study with 60
post-menopausal women who suffered hot flushes,
GBP appeared to be as effective as oestrogens in
relieving this annoying symptom [36]. In conclusion,
the data suggest that GBP may be effective in the
treatment of hot flushes in post-menopausal wom-
en. Data concerning excessive sweating in cancer [pa-
tients] are limited to a series of 9 patients who all
responded to GBP up to 1800 mg a day [37].
Pruritus
There are different mechanisms for pruritus and
one of them is pruritus due to neuropathy [38]. It is
thus logical that GBP was first applied in such con-
ditions as brachioradial pruritus [39–41] and notal-
gia paraesthetica [42]. Mendham et al reported a
positive effect in a series of 35 children with itchy
scars following burns [43]. However, the anti-pru-
ritic effects were also observed in conditions only
remotely connected to neuropathy. Twenty-five pa-
tients with uraemic pruritus were treated in a cross
over, placebo-controlled design [44]. Several patients
in this study responded to the treatment with GBP,
although the overall effect was not significant. In a
comment on this study it was concluded that to
avoid the nephrotoxicity of GBP, this drug should
be given in a low dose (100 mg) after every haemo-
dialysis session [45]. Overall, GBP is found to be
interesting and potentially effective in uraemic pru-
ritus [46–48]. GBP was also claimed to be effective
in pruritus of unknown origin [49].
GBP may be effective in the reduction of pruritus
caused by opioids [50–52]. However, GBP was found
to be ineffective in the treatment of the pruritus of
cholestasis, a condition known to be caused by en-
dogenous opioids [53]. Interestingly, there was a
suggestion that GBP was effective in several cases
of patients with cutaneous T-cell lymphoma and
Sézary Syndrome [54]. However, although still un-
confirmed this is of particular importance because
few other drugs appear to be effective for this syn-
drome and the pruritus is overwhelming.
There are few reports of the anti-pruritic effects
of PGB [55–57] and Stander et al, basing this on her
own and unconfirmed observations, has suggested
that PGB’s effect on pruritus is weaker than those
of GBP [58].
In conclusion GBP, but not PGB, seems to be
effective in different pruritic conditions, not only
those related to neuropathy and nerve damage.
Most important is the activity of GBP in uraemic
pruritus. Further studies should be undertaken to
confirm or refute this significant effect.
Restless legs syndrome
Restless legs syndrome (RLS) is a sensorimotor
disorder, characterized by an irresistible urge to
move the legs and is usually accompanied or caused
by uncomfortable and unpleasant sensations. It be-
gins or worsens during periods of rest or inactivity,
is partially or totally relieved by movement and is
exacerbated or occurs at night and in the evening.
Typically, the condition responds to dopaminergic
treatment. Theoretically, the anti-dopaminergic
drugs frequently used in palliative care, such as ha-
loperidol or metoclopramide, should increase the
frequency and intensity of RLS. However, this effect
has not been reported so far. Dopamine-resistant
RLS has been suggested to be responsive to GBP,
although without provision of any details or con-
trolled data. In one study GBP was compared with
ropinirole, a dopamine agonist, in its effectiveness
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in RLS. The study was randomized but not placebo
controlled. The authors concluded that both drugs
were equally effective in the treatment of RLS and
were equally well tolerated [59]. In two patient se-
ries GBP was found to be effective for RLS and trem-
ors [60, 61]. In a formal randomized, placebo-con-
trolled study GBP appeared to be effective in the
treatment of the symptoms of RLS. Meta-analysis
which included all trials with anti-epileptic drugs —
including GBP [62] — for RLS was inconclusive, main-
ly because of the scarcity of data [63].
PGB was reported to be effective in 16 patients
with RLS [64]. However, 3 other patients in this
study needed to discontinue therapy because of
intolerable adverse effects and loss of benefit.
Miscellanea
GBP appears to have been effective for a number
of other symptoms, including nausea and vomiting
[65–68], alcohol dependency [69–72], smoking ces-
sation [73], erythromelalgia [74], stiff-limb syndrome
[75], benign fasciculations [76] and symptoms of
hepatic encephalopathy [77]. The majority of these
claims are not supported by controlled trials.
Conclusion
GBP and PGB act through a diminishing of the
release of the neurotransmitters responsible for cen-
tral sensitization. These drugs are, therefore, poten-
tially effective for multiple symptoms that are relat-
ed to the increased excitation of the central nervous
system. Although most of the clinical data concerns
GBP, it is expected that PGB does not have an effect
on these symptoms that would be very much differ-
ent. The most important actions of GBP and PGB
are their effects on various forms of pruritus, in-
cluding uraemic pruritus, intractable hiccups and
hot flushes in post-menopausal women. Further
studies are needed to support other claims. From
not one study does it appear that PGB is more ef-
fective than GBP, which means that, for the time
being, GBP should be the preferred drug because of
economical reasons.
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